MedTrace Logo

Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment

NCT02935010 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 382

Last updated 2018-08-15

No results posted yet for this study

Summary

With markedly increased antibiotic resistance and unsatisfactory efficacies of common empiric eradication regimens in the mainland of China, tailored therapy may be the best choice to achieve good efficacy. This study compared the eradication rates, safety, and compliance of antibiotic sensitivity-based tailored therapy compared with empiric bismuth quadruple therapy in the naive patients with Helicobacter pylori infection.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Esomeprazole

proton pump inhibitor

DRUG

Bismuth Potassium Citrate

Gastric mucosal protective drug with anti-H. pylori effect

DRUG

Amoxicillin

antibiotic for H. pylori eradication

DRUG

Clarithromycin

antibiotic for H. pylori eradication

DRUG

Metronidazole

antibiotic for H. pylori eradication

DRUG

Levofloxacin

antibiotic for H. pylori eradication

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Hong Lu, M.D. · Renji Hospital, School of Medicine, Shanghai Jiao Tong University

  • Yunwei Sun, M.D. · Ruijin Hospital

  • Hong Gao, M.D. · Fudan University

  • Yan Zhao, M.D. · Shanghai Tenth People's Hospital, Tongji University

  • Gang Xu, M.D. · Shanghai General Hospital, Shanghai First People's Hospital, Shanghai Jiao Tong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-05
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02935010 on ClinicalTrials.gov